The Cancer Journal最新文献_第2页

Bruton Tyrosine Kinase Inhibitors 布鲁顿酪氨酸激酶抑制剂

The Cancer Journal Pub Date : 2019-11-01 DOI: 10.1097/PPO.0000000000000412

J. Burger

{"title":"Bruton Tyrosine Kinase Inhibitors","authors":"J. Burger","doi":"10.1097/PPO.0000000000000412","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000412","url":null,"abstract":"Abstract Bruton tyrosine kinase (BTK) is a nonreceptor tyrosine kinase that plays a central role in the signal transduction of the B-cell antigen receptor and other cell surface receptors, both in normal and malignant B lymphocytes. B-cell antigen receptor signaling is activated in secondary lymphatic organs and drives the proliferation of malignant B cells, including chronic lymphocytic leukemia (CLL) cells. During the last 10 years, BTK inhibitors (BTKis) are increasingly replacing chemotherapy-based regimen, especially in patients with CLL and mantle cell lymphoma (MCL). Bruton tyrosine kinase inhibitors are particularly active in patients with CLL and MCL, but also received approval for Waldenström macroglobulinemia, small lymphocytic lymphoma, marginal zone lymphoma, and chronic graft-versus-host disease. Current clinical practice is continuous long-term administration of BTKi, which can be complicated by adverse effects or the development of drug resistance. Alternatives to long-term use of BTKi are being developed, such as combination therapies, permitting for limited duration therapy. Second-generation BTKis are under development, which differ from ibrutinib, the first-in-class BTKi, in their specificity for BTK, and therefore may differentiate themselves from ibrutinib in terms of adverse effects or efficacy.","PeriodicalId":22430,"journal":{"name":"The Cancer Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80245669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 45

Targeted Therapies in Chronic Lymphocytic Leukemia 慢性淋巴细胞白血病的靶向治疗

The Cancer Journal Pub Date : 2019-11-01 DOI: 10.1097/PPO.0000000000000410

C. Ujjani, B. Cheson

{"title":"Targeted Therapies in Chronic Lymphocytic Leukemia","authors":"C. Ujjani, B. Cheson","doi":"10.1097/PPO.0000000000000410","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000410","url":null,"abstract":"Abstract Small molecule inhibitors, including B-cell receptor antagonists and B-cell lymphoma - 2 inhibitors, have revolutionized the treatment of chronic lymphocytic leukemia (CLL). These agents have improved outcomes for patients of all prognostic backgrounds, thus securing their role in the frontline setting. Impressive activity has been demonstrated both with monotherapy and in combination with other targeted therapeutics. The most important remaining question is whether to administer small molecule inhibitors in a sequential fashion or in combination with each other and/or anti-CD20–directed therapy. Together, a number of retrospective and prospective clinical trials have provided insight into patient outcomes with different sequencing and combination strategies. While rituximab does not appear to provide significant additional benefit to ibrutinib, the incorporation of venetoclax appears to enable a deeper response and allow for a shorter duration of therapy. How durable of a response this produces and whether patients can be effectively retreated with venetoclax remain unclear. As various targeted therapy doublets and triplets are explored, it is important to investigate whether they produce significant long-term benefits over monotherapy and whether these approaches are appropriate for all patients.","PeriodicalId":22430,"journal":{"name":"The Cancer Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75927600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted Therapies 靶向治疗时代慢性淋巴细胞白血病的现实证据

The Cancer Journal Pub Date : 2019-11-01 DOI: 10.1097/PPO.0000000000000407

P. Islam, A. Mato

引用次数: 4

Targeted Therapy in Chronic Lymphocytic Leukemia 慢性淋巴细胞白血病的靶向治疗

The Cancer Journal Pub Date : 2019-11-01 DOI: 10.1097/PPO.0000000000000416

T. Kipps, M. Choi

引用次数: 10

The Shifting Paradigm in Chronic Lymphocytic Leukemia 慢性淋巴细胞白血病的转移模式

The Cancer Journal Pub Date : 2019-11-01 DOI: 10.1097/PPO.0000000000000417

N. Jain, S. O'brien

引用次数: 6

Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia. 治疗慢性淋巴细胞白血病的新型靶向药物的成本效益。

The Cancer Journal Pub Date : 2019-11-01 DOI: 10.1097/PPO.0000000000000411

R Andrew Harkins, Sharvil P Patel, Christopher R Flowers

引用次数: 0

Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia 慢性淋巴细胞白血病对靶向药物的耐药机制

The Cancer Journal Pub Date : 2019-11-01 DOI: 10.1097/PPO.0000000000000406

A. Kittai, J. Woyach

引用次数: 12

Relevance of Minimal Residual Disease in the Era of Targeted Agents 靶向药物时代最小残留病的相关性

The Cancer Journal Pub Date : 2019-11-01 DOI: 10.1097/PPO.0000000000000413

S. Heltai, P. Ghia, L. Scarfò

引用次数: 7

Visit-to-Visit Hemoglobin A1c Variability Is Associated With Later Cancer Development in Patients With Diabetes Mellitus 就诊间糖化血红蛋白变异性与糖尿病患者晚期癌症发展相关

The Cancer Journal Pub Date : 2019-07-01 DOI: 10.1097/PPO.0000000000000387

Yuki Saito, H. Noto, O. Takahashi, D. Kobayashi

{"title":"Visit-to-Visit Hemoglobin A1c Variability Is Associated With Later Cancer Development in Patients With Diabetes Mellitus","authors":"Yuki Saito, H. Noto, O. Takahashi, D. Kobayashi","doi":"10.1097/PPO.0000000000000387","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000387","url":null,"abstract":"Purpose Recent studies have shown that patients with diabetes mellitus have a higher risk of tumorigenesis. However, the effect of glycemic variability on tumorigenesis among diabetic patients has not been well investigated. Hence, we performed a retrospective cohort study to analyze the effect of visit-to-visit hemoglobin A1c (HbA1c) variability and later onset of malignancies. Methods This study included 2640 patients with diabetes mellitus 50 years or older. To analyze visit-to-visit glycemic activity, we calculated intrapersonal SD of all recorded HbA1c and used SD-HbA1c as a measure of glycemic variability. Because the number of individual visits varied, we divided SD-HbA1c by visit times in order to adjust for the potential influence of visit time difference between individuals. Patients were divided into quartiles according to their HbA1c variability, and Cox regression models were used to evaluate the association between glycemic variability and later onset of tumorigenesis. Results Three hundred thirty patients (12.5%) developed malignancy during follow-up. The median follow-up period was 1511 days (4.1 years; interquartile range, 2487.5 days). Relative to the group with the lowest glycemic variability (first quartile), the groups with higher glycemic variability showed a dose-dependent association with tumorigenesis. The odds ratios for the second, third, and fourth quartiles were 1.20 (95% confidence interval, 0.88–1.65), 1.43 (1.02–2.00), and 2.19 (1.52–3.17), respectively. The mean HbA1c and diabetes mellitus duration periods were not significantly associated with tumorigenesis. This result was consistent when limiting the number of covariates. Conclusions These results demonstrated that visit-to-visit HbA1c variability is a potential risk factor for later tumorigenesis. The association may be mediated by oxidative stress or hormone variability. Routine cancer screening may be suggested for diabetic patients with unstable glycemic control.","PeriodicalId":22430,"journal":{"name":"The Cancer Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90858168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Clinical Applications of Next-Generation Sequencing in Precision Oncology. 下一代测序在精准肿瘤学中的临床应用。

The Cancer Journal Pub Date : 2019-07-01 DOI: 10.1097/PPO.0000000000000385

Chris A Karlovich, P Mickey Williams

引用次数: 0